Enhertu accepted via cancer drugs fund for HER2-positive breast cancer
Decision is based on results from the Phase II DESTINY-Breast01 trial
Read More
Tag: HER2-positive breast cancer
Long-term data shows promise in breast cancer biosimilar
The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.
Read More
NICE changes its mind on Perjeta
NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.
Read More
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
